Dekavil at the EULAR 2012

Dekavil inhibits the progression of collagen-induced arthritis, which is a mouse model for rheumatoid arthritis. You can look at the whole article here: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2787264/  
This immunocytokine is a combination of the F8 antibody (specific to a part of fibronectin) and interleukin-10 (IL-10). Predominantly monocytes produce IL-10, which effects immunoregulation and inflammation.
At the EULAR 2012 Meeting in Berlin Dekavil has been introduced in one study. M. Galeazzi and colleagues presented a phase Ib clinical trial with dekavil in combination with methotrexate. The study shows preliminary results, as it is still ongoing. Dekavil has been tolerated well. The authors report a surprising result of reaching ACR50 after 8 weeks.


[FRI0194] A PHASE IB CLINICAL TRIAL WITH DEKAVIL (F8-IL10), AN ANTI-INFLAMMATORY IMMUNOCYTOKINE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS, USED IN COMBINATION WITH METHOTREXATE
M. Galeazzi1, C. Baldi1, K. Schwager2, D. Neri3, L. Giovannoni4, E. Selvi1. 1Rheumatology Unit, University of Siena, Siena, Italy; 2Philochem AG, Otelfingen; 3Swiss Federal Institute of Technology, Zurich, Switzerland; 4Clinical Research Unit, Philogen S.p.a., Sovicille, Italy
Conclusions: The promising safety data about the clinical use of DEKAVIL, together with emerging signs of potent activity in heavily pre-treated patients, warrants future developments of the product in randomized clinical trials, which are currently in planning. An update of clinical data will be presented at the EULAR meeting.


Preliminary results of an ongoing phase Ib study. We shouldn’t get too excited, but there is a need of further clinical trials. Other competitors have started with less!